2Seventy Bio

2Seventy Bio Days Payable Outstanding

Delisted

The Days Payable Outstanding (DPO) of 2Seventy Bio (TSVT) as of Nov 8, 2026 is 17.07. In the previous year, Days Payable Outstanding (DPO) was 130.05 — a change of -86.88% (lower).

Days Payable Outstanding

17.07

YoY

-86.88%

Last updated:

Days Payable Outstanding (DPO) of 2Seventy Bio is 2024 17.07 . Days Payable Outstanding (DPO) of 2Seventy Bio was 2023 130.05 . It decreases by -86.88% lower compared to the previous year.

The 2Seventy Bio Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2019
2,498.99 USD
Jan 1, 2020
483.78 USD
Jan 1, 2021
873.56 USD
Jan 1, 2022
100.34 USD
Jan 1, 2023
130.05 USD
Jan 1, 2024
17.07 USD
The 2Seventy Bio Days Payable Outstanding history
YEARDays Payable OutstandingYoY
17.07-86.88%
130.05+29.61%
100.34-88.51%
873.56+80.57%
483.78-80.64%
2,498.99—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

2Seventy Bio Stock analysis

What does 2Seventy Bio do? 2seventy Bio, Inc. generates revenue through its cell and gene therapy programs, including SC-DARIC33 for pediatric relapsed and refractory acute myeloid leukemia and bbT369 for B-cell non-Hodgkin lymphoma. The company collaborates with Bristol Myers Squibb to deliver Abecma for multiple myeloma patients in the U.S., leveraging its T cell engineering and lentiviral vector technologies. Its clinical and preclinical programs, such as bbT4015 targeting MUC16, form the core of its product pipeline. The company focuses on developing targeted cellular therapies for cancer patients, with Bristol Myers Squibb as a key partner in commercializing Abecma. 2seventy Bio, Inc. operates in the biopharmaceutical sector, targeting patients with specific cancer types through its advanced therapies. Its products are developed using proprietary T cell engineering and lentiviral vector delivery systems. The company's revenue streams include clinical trial partnerships and potential future commercial sales of its therapies. Bristol Myers Squibb supports the U.S. distribution of Abecma, a key product in its portfolio. 2Seventy Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 2Seventy Bio stock

Days Payable Outstanding (DPO) of 2Seventy Bio is 17.07 in 2024.

Days Payable Outstanding (DPO) of 2Seventy Bio changed from 130.05 to 17.07, representing a -86.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) 2Seventy Bio since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s 2Seventy Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — 2Seventy Bio

All Key Metrics — 2Seventy Bio